This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinicaltrials holding great hope for the treatment of challenging and uncurable diseases.
Despite their exciting potential, the smooth operation of cell therapy development trials requires extraordinary orchestration, perfectly aligning the product and patient journeys. While clinicalsupply is essential to any successful trial, autologous cell therapy trials occupy the far end of the spectrum regarding risk tolerance.
According to Tufts Center for the Study of Drug Development (CSDD), in a typical Phase Ill clinicaltrial, 119 protocol deviations are implemented on average, involving approximately one-third of all patients participating in that trial. Seamless integration empowers data-driven decisions, fast.
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinicaltrials.
Modern software development concepts from ecommerce applications are helping eClinical applications meet the precise needs of each clinicaltrial. IRT solutions help clinicaltrial sponsors meet the complexities of patient randomization and clinicalsupply management. until the database lock of the system.
In this episode, you’ll learn about the world of ClinicalTrial Site Networks. There are advantages and disadvantages when it comes to being a standalone clinicaltrial site. Standalone clinicaltrial sites enjoy the freedom of running their own operations. This is where site networks come in.
Planning on running clinicaltrials in Japan? How can you reliably supply these studies? Discover Catalent’s clinicalsupply packaging facility in Shiga, Japan.
Avoiding “Customs Chaos” in ClinicalTrials Means Working Closely with Your Importer of Record Many global clinicaltrial shipments get muddled regarding the critical role and responsibilities of the importer of record (IOR) for clinicaltrials.
Avoiding “Customs Chaos” in ClinicalTrials Means Working Closely with Your Importer of Record Many global clinicaltrial shipments get muddled regarding the critical role and responsibilities of the importer of record (IOR) for clinicaltrials.
Analyzing the benefits and challenges of implementing direct-to-patient services in the clinicalsupply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market.
The benefits of developing a patient-centric clinicalsupply chain.
Add bookmark.
In this episode, I’m excited for you to learn about Heart Failure ClinicalTrials for medical devices. Veeva connects patients, sites, and sponsors, on a single technology ecosystem to make clinicaltrials easier and faster. Our guest today is Sonna Patel-Raman. I’m particularly excited about Veeva SiteVault.
The global landscape of clinicaltrials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinicalsupply challenges, including patient demand and reducing delays.
The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinicalsupply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialized, ultra-low temperature storage capabilities. With sites in the U.S.,
Unlike commercial pharmaceutical packaging, the primary consideration in clinicaltrial packaging is protecting the product quality and reliability for research. Finding the best clinicaltrial packaging services providers. Clinicaltrial packaging and labelling solutions.
Find out solutions to mitigate the impact from clinicalsupply chain risk and discover how to improve dynamic drug supply forecasting strategies. Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk.
NUCLIDIUM has signed a strategic collaboration deal with PharmaLogic for the manufacturing and clinicalsupply of copper-based theranostics ⁶¹Cu in the US. ⁶¹Cu It will also enable NUCLIDIUM to achieve a sustainable supply of ⁶¹Cu in the US for its proposed clinicaltrials and upcoming commercialised products.
Randomization and TrialSupply Management (RTSM) play a pivotal role in the successful execution of clinicaltrials. As the complexity of clinicaltrials continues to increase, especially with the rise of multi-center, adaptive, and decentralized trials, the need for robust RTSM systems has become more critical than ever.
The Phase I clinicaltrial that is underway is assessing SY-5609 plus chemotherapy in subjects with pancreatic cancer whose disease has advanced after Folfirinox treatment. . Tolerability and safety, as well as efficacy parameters, such as disease control rate and progression-free survival, will be analysed in the trial. .
Overview: Clinical site monitoring metrics and Key Performance Indicators (KPIs) are fundamental tools in the realm of clinicaltrial management. They provide a way to quantify and evaluate critical aspects of a clinicaltrial’s performance at individual investigative sites.
Supply chain uncertainty is a challenge every clinicalsupply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinicaltrial designs and a lack of visibility in the supply chain. Accelerating your clinicaltrialsupply through digitalization.
Collaboration provides clinicaltrial sponsors with access to the world’s most efficient clinicalsupply processes using a single contract. As a result, global clinicalsupply and operations teams can now single source their commercial drug requirements by utilizing two best-in-class solution providers.
According to GlobalData’s clinicaltrials database, there are currently 1,231 planned and ongoing trials for gene therapies and gene-modified cell therapies alone. Cell and gene therapies are not your typical clinicalsupply chain.
The agreement also puts in place a three year clinicalsupply agreement for the two companies. Under the terms of the deal, Oxford Biomedica will receive an undisclosed upfront payment, with additional payment related to development and manufacturing of lentiviral vectors for use in clinicaltrials.
Do consider the impact of decisions A lot of decisions get made during the design of a clinicaltrial; be they decisions on data or packaging and distribution design. Do think study, not software A clinicaltrial comprises more than just RTSM data, EDC data, or lab data—it’s a convergence of various data points.
The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01.
VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinicaltrial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease. Pfizer is collaborating with Vivet on the clinicalsupply of VTX-801 for the Phase 1/2 clinicaltrial.
Do consider the impact of decisions A lot of decisions get made during the design of a clinicaltrial; be they decisions on data or packaging and distribution design. Do think study, not software A clinicaltrial comprises more than just RTSM data, EDC data, or lab data—it’s a convergence of various data points.
Do consider the impact of decisions A lot of decisions get made during the design of a clinicaltrial; be they decisions on data or packaging and distribution design. Do think study, not software A clinicaltrial comprises more than just RTSM data, EDC data, or lab data—it’s a convergence of various data points.
Among the factors that may result in differences are MorphoSys’ expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical (..)
Our goal should be to deliver a clinicaltrial suite that works with the trial, with the users, and most critically, with the patients so that the study as a whole is successful. We need to start thinking about trials as part of a portfolio, rather than per study systems/implementations/designs.
Our goal should be to deliver a clinicaltrial suite that works with the trial, with the users, and most critically, with the patients so that the study as a whole is successful. We need to start thinking about trials as part of a portfolio, rather than per study systems/implementations/designs.
Our goal should be to deliver a clinicaltrial suite that works with the trial, with the users, and most critically, with the patients so that the study as a whole is successful. We need to start thinking about trials as part of a portfolio, rather than per study systems/implementations/designs.
Do consider the impact of decisions A lot of decisions get made during the design of a clinicaltrial; be they decisions on data or packaging and distribution design. Do think study, not software A clinicaltrial comprises more than just RTSM data, EDC data, or lab data—it’s a convergence of various data points.
Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinicalsupply and commercial launch. At the BIO International Convention, Carey Connolly, Ph.D.,
Our goal should be to deliver a clinicaltrial suite that works with the trial, with the users, and most critically, with the patients so that the study as a whole is successful. We need to start thinking about trials as part of a portfolio, rather than per study systems/implementations/designs.
“In collaboration with our partner, Novartis, our team continues to move at extraordinary speed from idea to bench to clinicaltrials, driven by a common desire to help patients against this devastating disease and help bring the world back closer to normalcy.” Chief Medical Officer of Molecular Partners.
Concerns of Early Deaths The expanded approvals come after the FDA had flagged reports of early deaths in clinicaltrials evaluating the therapies in earlier treatment line settings. This prompted the convening of the ODAC advisory committee to weigh in on the concern.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drug supply is managed.
Under the agreement, during the option period, Molecular Partners will conduct Phase 1 clinicaltrials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinicaltrials, with Molecular Partners as sponsor of these trials.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content